EU Says J&J, Novartis Pay-For-Delay Breached Antitrust Laws

Law360, New York (January 31, 2013, 1:06 PM EST) -- European antitrust regulators said Thursday they believed drugmakers Johnson & Johnson and Novartis AG violated European competition law by inking an agreement to delay the launch of cheaper generic drugs in the Netherlands.

After more than a year of investigation, the European Commission sent formal objections that accused Dutch J&J unit Janssen-Cilag of paying off Novartis subsidiary Sandoz to not launch a generic version of the painkiller fentanyl.

The so-called pay-for-delay deal eliminated any competition for J&J's fentanyl from July 2005 until December 2006, keeping the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.